K
Karel Geboes
Researcher at Catholic University of Leuven
Publications - 366
Citations - 16556
Karel Geboes is an academic researcher from Catholic University of Leuven. The author has contributed to research in topics: Crohn's disease & Ulcerative colitis. The author has an hindex of 52, co-authored 364 publications receiving 15723 citations. Previous affiliations of Karel Geboes include Katholieke Universiteit Leuven & Pasteur Institute.
Papers
More filters
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Gert Van Assche,Marc Van Ranst,Raphael Sciot,Bénédicte Dubois,Severine Vermeire,Maja Noman,Jannick Verbeeck,Karel Geboes,Wim Robberecht,Paul Rutgeerts +9 more
TL;DR: Analysis of frozen serum samples showed that JC virus DNA had appeared in the serum three months after the initiation of open-label natalizumab monotherapy and two months before the appearance of symptomatic PML, suggesting that anti-alpha4-integrin therapy can result in JC virus-induced PML.
Journal ArticleDOI
Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis
Axel Dignass,Rami Eliakim,Fernando Magro,Christian Maaser,Yehuda Chowers,Karel Geboes,Gerassimos J. Mantzaris,Walter Reinisch,Jean-Frederic Colombel,Severine Vermeire,Simon Travis,James O. Lindsay,Gert Van Assche +12 more
TL;DR: The aim of the Consensus is to promote a European perspective on the management of ulcerative colitis and its dilemmas to avoid duplication of effort in the future.
Journal ArticleDOI
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.
Geert D'Haens,S. J. H. Van Deventer,R. A. van Hogezand,DM Chalmers,C Kothe,F Baert,T. Braakman,T. F. Schaible,Karel Geboes,Paul Rutgeerts +9 more
TL;DR: Clinical improvement after infliximab therapy in active Crohn's disease is accompanied by significant healing of endoscopic lesions and disappearance of the mucosal inflammatory infiltrate and architectural changes persisted in most patients.
Journal ArticleDOI
Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery.
Paul Rutgeerts,Karel Geboes,Gaston Vantrappen,Raymond Kerremans,J. L. Coenegrachts,Georges Coremans +5 more
TL;DR: It is suggested that recurrence of Crohn's disease almost always develops in the first year after the operation, and significant endoscopic lesions may be present without clinical symptoms, particularly in the earlier stages of the disease.